
Welcome to
Gateway Pharmaceutical
Gateway Pharmaceutical is a specialty company focusing on 505(b)(2) new NDAs of antibiotics for target delivery of drugs to local bacteria, to improve efficacy and reduce antibiotic resistance.
​
Our Team has extensive pharmaceutical industrial experience in pharmaceutical CMC, product development, manufacturing, pharmacokinetics, clinical design and studies, and regulatory submission.

Our Mission
Innovating site-specific delivery of antibiotics to combat antibiotic resistance threats to the United States and the World.

BioSTL Award in 2018 Venture Showcase
September, 2020 – We received the NIH NIAID Pre-Clinical Service Award on GMP manufacturing of Metronidazole Delayed-Release Capsules for treating Clostridium difficile infection.
March, 2020 – Our key colon-delivery patent 10,588,864 received approval from the US PTO.
​
August, 2018 – We received the NIH SBIR Phase I grant on Metronidazole Colon-Delivery for treating Clostridium difficile Infection.
​
November, 2018 – Gateway won the BioSTL Award on the 10th Startup Connection Venture Showcase in St. Louis.